My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

96.74 -7.57 (-7.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,153,824
Open 101.60
Bid (Size) 96.00 (1)
Ask (Size) 96.74 (1)
Prev. Close 104.31
Today's Range 90.12 - 102.13
52wk Range 81.20 - 131.49
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why BioNTech Stock Sank by More Than 7% Today
The type of vaccine it's most famous for might be cast in a very unflattering light in the very near future.. 
Via The Motley Fool
Topics Death Government
Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths
Shares of COVID-19 vaccine makers are trading lower Friday. Vaccine stocks fell Friday on a Washington Post report that Trump administration officials plan to link the shots to 25 child deaths. 
Via Benzinga
Topics Government

Performance

YTD
-16.1%
-16.1%
1 Month
-12.8%
-12.8%
3 Month
-7.8%
-7.8%
6 Month
-0.7%
-0.7%
1 Year
-2.5%
-2.5%

More News

Read More
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
Via Investor's Business Daily
Topics Government
Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults
Via Benzinga
Pfizer, BioNTech’s Updated COVID-19 Vaccine Shows Robust Immune Response In Late-Stage Study – More Details Inside
Via Stocktwits
What Analysts Are Saying About BioNTech Stock
Via Benzinga
Why Did BioNTech Stock Surge 10% Pre-Market Today?
Via Stocktwits
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
Via Benzinga
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
From BioNTech SE
Via GlobeNewswire
Pfizer, BioNTech Get FDA Clearance For Updated Covid Vaccine In Senior Adults And Younger At-Risk Population
Via Stocktwits
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch
Via Investor's Business Daily
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
From Pfizer Inc.
Via Business Wire
Why BioNTech Stock Crushed the Market Today
Via The Motley Fool
Guidewire Software, Samsara, Zumiez And Other Big Stocks Moving Higher On Friday
Via Benzinga
Shots Fired! After RFK Jr.'s Senate Grilling, Will Pfizer, Moderna Survive The Battle In D.C.?
Via Investor's Business Daily
BioNTech Surges 10% On Promising Test Results For Its Cancer Smart Bomb
Via Investor's Business Daily
BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data
Via Benzinga
Robert Kennedy Jr.'s Leadership Can Only Bring More 'Harm,' Says Top Ex-CDC Official: 'Undoing Of Vaccination' In Works
Via Benzinga
Marvell Technology, eBay, And DexCom Are Among Top 10 Large Cap Losers Last Week (August 25-August 29): Are The Others In Your Portfolio?
Via Benzinga
RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines
Via Benzinga
RFK Jr. Makes Good On Promise To End Covid Vaccine Mandate. BioNTech Tumbles.
Via Investor's Business Daily
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
From BioNTech SE
Via GlobeNewswire
Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'
Via Benzinga
Topics Government
3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is BioNTech SE - American Depositary Shares publicly traded?
Yes, BioNTech SE - American Depositary Shares is publicly traded.
What exchange does BioNTech SE - American Depositary Shares trade on?
BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BioNTech SE - American Depositary Shares?
The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market
What is the current price of BioNTech SE - American Depositary Shares?
The current price of BioNTech SE - American Depositary Shares is 96.74
When was BioNTech SE - American Depositary Shares last traded?
The last trade of BioNTech SE - American Depositary Shares was at 09/12/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.